|Bid||3.4000 x 800|
|Ask||3.6800 x 1000|
|Day's Range||3.3600 - 3.6300|
|52 Week Range||3.0300 - 6.8400|
|Beta (5Y Monthly)||1.40|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 03, 2021 - Aug 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.13|
CAMBRIDGE, Mass., July 22, 2021--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it plans to report its second quarter 2021 financial results and other business updates on July 29, 2021. The company will host a conference call at 8:30 a.m. ET that morning.
CAMBRIDGE, Mass., June 30, 2021--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it has activated initial clinical sites and patient screening for its global Phase 2 clinical trial of AXA1665, the company’s multi-targeted oral product candidate for the reduction in risk of recurrent overt hepatic encephalopathy (OHE).
Time in the market beats timing the market, as the old adage goes. This platitude plays particularly well regarding biotechnology stocks, as one will want to be invested in these stocks well before any big news comes out. Axcella Health Inc. (AXLA) is no exception, as the company is making strides on breakthrough therapies. Analysts are bullish on the stock. One such analyst is Keay Nakae of Chardan Capital Markets, who assigned a Buy rating and a price target of $10. While this price target rep